Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.
复制标题
DOI：
10.1002/cncr.24714
复制
发表时间：
2010-01-01
期刊：
影响因子：
6.2
通讯作者：
Cheson, Bruce D.
中科院分区：
文献类型：
--
作者：
Kahl, Brad S.;Bartlett, Nancy L.;Leonard, John P.;Chen, Ling;Ganjoo, Kristen;Williams, Michael E.;Czuczman, Myron S.;Robinson, K. Sue;Joyce, Robin;van der Jagt, Richard H.;Cheson, Bruce D.
盐酸苯达莫司汀是一种新型烷化剂。在这项多中心研究中，作者评估了单药苯达莫司汀对利妥昔单抗难治性惰性 B 细胞淋巴瘤患者的疗效和毒性。符合条件的患者（N = 100，年龄 31-84 岁）在第 1 天和第 2 天每 21 天接受 120 mg/m2 剂量的苯达莫司汀静脉输注，共 6 至 8 个周期。组织学包括滤泡性淋巴瘤（62%）、小淋巴细胞性淋巴瘤（21%）和边缘区淋巴瘤（16%）。患者之前平均接受过 2 种化疗方案（范围为 0-6 种之前的化疗方案），并且 36% 的患者对其最近的化疗方案耐药。主要终点包括总体缓解率（ORR）和缓解持续时间（DOR）。次要终点是安全性和无进展生存期（PFS）。观察到的 ORR 为 75%（完全缓解率为 14%，未确认完全缓解率为 3%，部分缓解率为 58%）。中位 DOR 为 9.2 个月，中位 PFS 为 9.3 个月。六例死亡被认为可能与治疗有关。 3 级或 4 级（使用国家癌症研究所通用毒性标准 [3.0.19 版] 确定。可逆性血液学毒性包括中性粒细胞减少症 (61%)、血小板减少症 (25%) 和贫血 (10%)。最常见的非血液学不良事件（任何级别）包括恶心 (77%)、感染 (69%)、疲劳 (64%)、腹泻 (42%)、呕吐（40%）、发热（36%）、便秘（31%）和厌食（24%），单药苯达莫司汀在复发性、利妥昔单抗难治性惰性 B 细胞淋巴瘤患者中产生了较高的客观缓解率和可接受的毒性。
Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single-agent bendamustine in patients with rituximab-refractory, indolent B-cell lymphoma. Eligible patients (N = 100, ages 31-84 years) received bendamustine at a dose of 120 mg/m2 by intravenous infusion on Days 1 and 2 every 21 days for 6 to 8 cycles. Histologies included follicular (62%), small lymphocytic (21%), and marginal zone (16%) lymphomas. Patients had received a median of 2 previous regimens (range, 0-6 previous regimens), and 36%were refractory to their most recent chemotherapy regimen. Primary endpoints included overall response rate (ORR) and duration of response (DOR). Secondary endpoints were safety and progression-free survival (PFS). An ORR of 75% (a 14% complete response rate, a 3% unconfirmed complete response rate, and a 58% partial response rate) was observed. The median DOR was 9.2 months, and median PFS was 9.3 months. Six deaths were considered to be possibly treatment related. Grade 3 or 4 (determined using National Cancer Institute Common Toxicity Criteria [version 3.0.19]. reversible hematologic toxicities included neutropenia (61%), thrombocytopenia (25%), and anemia (10%). The most frequent nonhematologic adverse events (any grade) included nausea (77%), infection (69%), fatigue (64%), diarrhea (42%), vomiting (40%), pyrexia (36%), constipation (31%), and anorexia (24%). Single-agent bendamustine produced a high rate of objective responses with acceptable toxicity in patients with recurrent, rituximab-refractory indolent B-cell lymphoma.
登录
查看更多内容
影响因子：
20.3
作者：
Marcus, R;Imrie, K;Smith, P
通讯作者：
Smith, P
影响因子：
20.3
作者：
Hiddemann, W;Kneba, M;Unterhalt, M
通讯作者：
Unterhalt, M
影响因子：
45.3
作者：
Herold, Michael;Haas, Antje;von Gruenhagen, Ullrich
通讯作者：
von Gruenhagen, Ullrich
影响因子：
11.5
作者：
Leoni, Lorenzo M.;Bailey, Brandi;Niemeyer, Christina C.
通讯作者：
Niemeyer, Christina C.
影响因子：
2.6
作者：
Koenigsmann, M;Knauf, WU;Franke, A
通讯作者：
Franke, A